
Please try another search
The post-election biotech honeymoon is over. Shares of the iShares Nasdaq Biotechnology ETF IBB are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.
Immediately following the election, IBB soared more than 9% as investors assumed that Trump would be much less likely to crack down on exorbitant drug price hikes than Hillary Clinton. After all, Clinton had put drug prices at the forefront of her campaign, while Trump is typically an outspoken supporter of deregulation.
In an interview with Time, which recently named him its “Person of the Year,” the president-elect promised to lower the cost of costly medications and suggested that investors may have misread his intentions.
“I’m going to bring down drug price,” Trump told Time. “I don’t like what has happened with drug prices.”
Trump’s warning was, as usual, concise and vague, but the message clearly resonated with biotech investors. Companies with existing price scandals, such as Mylan (NASDAQ:MYL) , felt the brunt of the sell-off today, while ETFs like IBB and the SPDR S&P Biotech (MX:XBI) ETF XBI highlighted the range of the trading.
Interestingly enough, Trump’s has previously promised to roll back FDA regulations to make things easier for companies to do business. It looks like Trump’s FDA promises could be more focused on food and farming regulations now, as a move to bring drug costs down would imply some sort of intervention in the pharmaceuticals industry.
Stocks that Aren't in the News. Yet.
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of +26% per year. See these high-potential stocks free >>
Defense stocks took a tumble heading into 2025 as President Trump returned to the White House for his second term. Trump has stated his intent as a peacemaker to bring the wars in...
Using the Elliott Wave Principle (EWP), we have been tracking the most likely path forward for the Nasdaq 100 (NDX). Although there are many ways to navigate the markets and to...
Investors are on edge about what tariff policy means for markets Coming off a strong Q4 earnings season, fresh February corporate sales figures can help assess the macro...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.